The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective - HAL Accéder directement au contenu
Article dans une revue The Journal of Allergy and Clinical Immunology: In Practice Année : 2021

The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

Marek Jutel
Alvaro Cruz
Mohamed Shamji

Résumé

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.
Fichier principal
Vignette du fichier
S2213219821002403.pdf ( 265.26 Ko ) Télécharger
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-03672676, version 1 (09-05-2023)

Licence

Paternité - Pas d'utilisation commerciale - CC BY 4.0

Identifiants

Citer

Jean Bousquet, Marek Jutel, Oliver Pfaar, Joao Fonseca, Ioana Agache, et al.. The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. The Journal of Allergy and Clinical Immunology: In Practice, 2021, 9 (5), pp.1805-1812. ⟨10.1016/j.jaip.2021.02.035⟩. ⟨hal-03672676⟩
20 Consultations
27 Téléchargements
Dernière date de mise à jour le 26/06/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus